A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia) in Patients With Postmenopausal Osteoporosis
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Teva Pharmaceuticals USA
- 21 Jun 2023 Status changed from active, no longer recruiting to completed.
- 01 Feb 2023 Planned End Date changed from 31 Dec 2023 to 15 Jul 2023.
- 16 Dec 2021 Status changed from recruiting to active, no longer recruiting.